+关注
stardustttt
暂无个人介绍
IP属地：未知
5
关注
1
粉丝
0
主题
0
勋章
主贴
热门
stardustttt
2021-11-17
$Lucid Group Inc(LCID)$
what is the good price to buy more @-@
stardustttt
2021-11-10
$SOS Limited(SOS)$
🥲🥲
stardustttt
2021-11-02
$Bon Natural Life Ltd(BON)$
share
stardustttt
2021-10-29
Great ariticle, would you like to share it?
抱歉，原内容已删除
stardustttt
2021-10-20
🙏🏻
抱歉，原内容已删除
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":3585806154552757,"uuid":"3585806154552757","gmtCreate":1622712242442,"gmtModify":1635509358281,"name":"stardustttt","pinyin":"stardustttt","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/acd24cad26743061551c18540659b201","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":5,"tweetSize":5,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.10.19","exceedPercentage":"60.53%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.10.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":871754750,"gmtCreate":1637115759295,"gmtModify":1637115759433,"author":{"id":"3585806154552757","authorId":"3585806154552757","name":"stardustttt","avatar":"https://static.tigerbbs.com/acd24cad26743061551c18540659b201","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/LCID\">$Lucid Group Inc(LCID)$</a>what is the good price to buy more @-@","listText":"<a href=\"https://laohu8.com/S/LCID\">$Lucid Group Inc(LCID)$</a>what is the good price to buy more @-@","text":"$Lucid Group Inc(LCID)$what is the good price to buy more @-@","images":[{"img":"https://static.tigerbbs.com/942b33defaa5c9d340e4d5019434a37e","width":"1170","height":"2292"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/871754750","isVote":1,"tweetType":1,"viewCount":151,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":847748377,"gmtCreate":1636555923197,"gmtModify":1636555986626,"author":{"id":"3585806154552757","authorId":"3585806154552757","name":"stardustttt","avatar":"https://static.tigerbbs.com/acd24cad26743061551c18540659b201","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SOS\">$SOS Limited(SOS)$</a>🥲🥲","listText":"<a href=\"https://laohu8.com/S/SOS\">$SOS Limited(SOS)$</a>🥲🥲","text":"$SOS Limited(SOS)$🥲🥲","images":[{"img":"https://static.tigerbbs.com/5512c7b223b1932beb539be7f7a9e177","width":"1170","height":"2292"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/847748377","isVote":1,"tweetType":1,"viewCount":295,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":843859012,"gmtCreate":1635818931729,"gmtModify":1635818931729,"author":{"id":"3585806154552757","authorId":"3585806154552757","name":"stardustttt","avatar":"https://static.tigerbbs.com/acd24cad26743061551c18540659b201","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BON\">$Bon Natural Life Ltd(BON)$</a>share","listText":"<a href=\"https://laohu8.com/S/BON\">$Bon Natural Life Ltd(BON)$</a>share","text":"$Bon Natural Life Ltd(BON)$share","images":[{"img":"https://static.tigerbbs.com/542b38da9af5b8bc31498eade8808201","width":"1170","height":"2292"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/843859012","isVote":1,"tweetType":1,"viewCount":939,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":857389869,"gmtCreate":1635508315326,"gmtModify":1635508315440,"author":{"id":"3585806154552757","authorId":"3585806154552757","name":"stardustttt","avatar":"https://static.tigerbbs.com/acd24cad26743061551c18540659b201","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/857389869","repostId":"1140565656","repostType":2,"isVote":1,"tweetType":1,"viewCount":210,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":859590245,"gmtCreate":1634707217315,"gmtModify":1634707277035,"author":{"id":"3585806154552757","authorId":"3585806154552757","name":"stardustttt","avatar":"https://static.tigerbbs.com/acd24cad26743061551c18540659b201","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"🙏🏻","listText":"🙏🏻","text":"🙏🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/859590245","repostId":"2176108187","repostType":4,"isVote":1,"tweetType":1,"viewCount":482,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"hots":[{"id":847748377,"gmtCreate":1636555923197,"gmtModify":1636555986626,"author":{"id":"3585806154552757","authorId":"3585806154552757","name":"stardustttt","avatar":"https://static.tigerbbs.com/acd24cad26743061551c18540659b201","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SOS\">$SOS Limited(SOS)$</a>🥲🥲","listText":"<a href=\"https://laohu8.com/S/SOS\">$SOS Limited(SOS)$</a>🥲🥲","text":"$SOS Limited(SOS)$🥲🥲","images":[{"img":"https://static.tigerbbs.com/5512c7b223b1932beb539be7f7a9e177","width":"1170","height":"2292"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/847748377","isVote":1,"tweetType":1,"viewCount":295,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":871754750,"gmtCreate":1637115759295,"gmtModify":1637115759433,"author":{"id":"3585806154552757","authorId":"3585806154552757","name":"stardustttt","avatar":"https://static.tigerbbs.com/acd24cad26743061551c18540659b201","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/LCID\">$Lucid Group Inc(LCID)$</a>what is the good price to buy more @-@","listText":"<a href=\"https://laohu8.com/S/LCID\">$Lucid Group Inc(LCID)$</a>what is the good price to buy more @-@","text":"$Lucid Group Inc(LCID)$what is the good price to buy more @-@","images":[{"img":"https://static.tigerbbs.com/942b33defaa5c9d340e4d5019434a37e","width":"1170","height":"2292"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/871754750","isVote":1,"tweetType":1,"viewCount":151,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":843859012,"gmtCreate":1635818931729,"gmtModify":1635818931729,"author":{"id":"3585806154552757","authorId":"3585806154552757","name":"stardustttt","avatar":"https://static.tigerbbs.com/acd24cad26743061551c18540659b201","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/BON\">$Bon Natural Life Ltd(BON)$</a>share","listText":"<a href=\"https://laohu8.com/S/BON\">$Bon Natural Life Ltd(BON)$</a>share","text":"$Bon Natural Life Ltd(BON)$share","images":[{"img":"https://static.tigerbbs.com/542b38da9af5b8bc31498eade8808201","width":"1170","height":"2292"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/843859012","isVote":1,"tweetType":1,"viewCount":939,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":859590245,"gmtCreate":1634707217315,"gmtModify":1634707277035,"author":{"id":"3585806154552757","authorId":"3585806154552757","name":"stardustttt","avatar":"https://static.tigerbbs.com/acd24cad26743061551c18540659b201","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"🙏🏻","listText":"🙏🏻","text":"🙏🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/859590245","repostId":"2176108187","repostType":4,"repost":{"id":"2176108187","pubTimestamp":1634699563,"share":"https://www.laohu8.com/m/news/2176108187?lang=&edition=full","pubTime":"2021-10-20 11:12","market":"us","language":"en","title":"3 Top Oil Stocks to Buy as Crude Oil Barrels Toward $85","url":"https://stock-news.laohu8.com/highlight/detail?id=2176108187","media":"Motley Fool","summary":"Crude oil continues to rally, which should benefit this trio of low-cost oil producers.","content":"<p>Oil prices continue to march higher. Brent, the global oil benchmark, recently touched $85 a barrel, while WTI, the U.S. oil price benchmark, is just a couple of dollars behind. Crude prices are pushing levels not seen since 2014. </p>\n<p>Oil could have further to run. Soaring coal and natural gas prices are forcing power producers in Asia to burn oil, further tightening global supplies.</p>\n<p>The potential for even higher oil prices means oil companies could produce even bigger cash windfalls. Three oil companies positioned to cash in on this market are <b>ConocoPhillips</b> (NYSE:COP), <b>Devon Energy</b> (NYSE:DVN), and <b>Pioneer Natural Resources</b> (NYSE:PXD). Here's why that makes them great oil stocks to consider buying in the current environment.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/efa46b1b23a84d17461457779462d280\" tg-width=\"700\" tg-height=\"465\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Enhancing an already strong plan</h2>\n<p>ConocoPhillips built a huge cash war chest in recent years, positioning it to take advantage of opportunities in the oil market. The first <a href=\"https://laohu8.com/S/AONE.U\">one</a> arose last year as it acquired Concho Resources amid the market turmoil to enhance its low-cost position in the oil-rich Permian Basin. The $9.7 billion all-stock deal reduced its average cost of supply below $30 WTI. </p>\n<p>Meanwhile, the company recently took advantage of another opportunity. Global energy giant <b>Royal Dutch</b> <b>Shell</b> (NYSE:RDS.A)(NYSE:RDS.B) is transitioning away from oil due to climate change concerns. Because of that, it put its Permian Basin assets up for sale, which ConocoPhillips scooped up for $9.5 billion in cash. That's a dirt-cheap price since the assets were on track to produce $1.9 billion in free cash flow over the next year based on the oil price outlook when it announced the deal last month. With oil continuing to rise, they could produce even more cash. </p>\n<p>That acquisition will enhance ConocoPhillips' operating plan, which was already on track to produce a whopping $70 billion in free cash flow through 2030, assuming that oil prices average $50 a barrel. With crude well over that level, ConocoPhillips could produce an even bigger gusher. It intends to use those funds to repay debt, grow its dividend, and repurchase shares, all of which should create additional value for its shareholders.</p>\n<h2>A growing dividend gusher</h2>\n<p>Devon Energy also took advantage of last year's oil market turmoil to make a needle-moving acquisition, merging with WPX Energy in a $12 billion deal. That combination reduced its costs so that Devon could fund its business at $33 WTI this year. Because of that low cost, Devon also launched the industry's first fixed-plus-variable dividend program to return more of its free cash flow to investors. </p>\n<p>With oil prices rising, Devon Energy's dividend payments have become bigger. In addition to its base quarterly dividend rate of $0.11 per share, Devon has paid out additional dividends of $0.19, $0.23, and $0.38 per share over the last three quarters. </p>\n<p>The variable payments will likely continue rising. Devon only realized $50.34 per barrel for its oil during the second quarter because its oil hedges cost it $13.29 per barrel. With those lower-priced hedges about to expire, Devon's cash flow should keep rising even if crude prices cool off. It plans to pay out up to 50% of its free cash flow via variable dividends each quarter, suggesting investors could continue reaping a windfall. </p>\n<h2>Accelerating the plan</h2>\n<p>Pioneer Natural Resources also took advantage of the oil market turmoil to bolster its oil business over the past year. It acquired <a href=\"https://laohu8.com/S/PE\">Parsley Energy</a> in a $7.6 billion deal last October and spent $6.4 billion to purchase DoublePoint Energy this April. Both transactions increased its scale in the Permian Basin, which helped reduce its costs so that it can produce more oil for less money. </p>\n<p>Pioneer's initial plan was to start returning some of its growing free cash flow to shareholders next year by adopting a similar dividend framework as Devon. However, booming oil prices drove Pioneer to accelerate its variable dividend program by declaring its first additional payment in August. At $1.51 per share, it was almost triple its base dividend of $0.51 per share. With oil prices rallying and Pioneer's cost-saving initiatives starting to deliver results, that payout could continue growing in the coming quarters. </p>\n<h2>Cashing in on higher crude oil prices</h2>\n<p>ConocoPhillips, Devon Energy, and Pioneer Natural Resources took advantage of last year's oil market turbulence to bolster their oil businesses by making needle-moving acquisitions. Those deals boosted their oil production while reducing costs, positioning all three to generate more cash flow. Because of that, they're cashing in on higher oil prices these days. That's giving them the funds to reward investors with higher dividends and share repurchases. Those shareholder returns will likely continue growing along with oil prices, making this trio stand out as some of the top oil stocks to consider buying as crude oil barrels toward $85.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Top Oil Stocks to Buy as Crude Oil Barrels Toward $85</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Top Oil Stocks to Buy as Crude Oil Barrels Toward $85\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-20 11:12 GMT+8 <a href=https://www.fool.com/investing/2021/10/19/3-top-oil-stocks-to-buy-as-crude-oil-barrels-towar/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Oil prices continue to march higher. Brent, the global oil benchmark, recently touched $85 a barrel, while WTI, the U.S. oil price benchmark, is just a couple of dollars behind. Crude prices are ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/10/19/3-top-oil-stocks-to-buy-as-crude-oil-barrels-towar/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DVN":"德文能源","COP":"康菲石油","PXD":"先锋自然资源"},"source_url":"https://www.fool.com/investing/2021/10/19/3-top-oil-stocks-to-buy-as-crude-oil-barrels-towar/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2176108187","content_text":"Oil prices continue to march higher. Brent, the global oil benchmark, recently touched $85 a barrel, while WTI, the U.S. oil price benchmark, is just a couple of dollars behind. Crude prices are pushing levels not seen since 2014. \nOil could have further to run. Soaring coal and natural gas prices are forcing power producers in Asia to burn oil, further tightening global supplies.\nThe potential for even higher oil prices means oil companies could produce even bigger cash windfalls. Three oil companies positioned to cash in on this market are ConocoPhillips (NYSE:COP), Devon Energy (NYSE:DVN), and Pioneer Natural Resources (NYSE:PXD). Here's why that makes them great oil stocks to consider buying in the current environment.\nImage source: Getty Images.\nEnhancing an already strong plan\nConocoPhillips built a huge cash war chest in recent years, positioning it to take advantage of opportunities in the oil market. The first one arose last year as it acquired Concho Resources amid the market turmoil to enhance its low-cost position in the oil-rich Permian Basin. The $9.7 billion all-stock deal reduced its average cost of supply below $30 WTI. \nMeanwhile, the company recently took advantage of another opportunity. Global energy giant Royal Dutch Shell (NYSE:RDS.A)(NYSE:RDS.B) is transitioning away from oil due to climate change concerns. Because of that, it put its Permian Basin assets up for sale, which ConocoPhillips scooped up for $9.5 billion in cash. That's a dirt-cheap price since the assets were on track to produce $1.9 billion in free cash flow over the next year based on the oil price outlook when it announced the deal last month. With oil continuing to rise, they could produce even more cash. \nThat acquisition will enhance ConocoPhillips' operating plan, which was already on track to produce a whopping $70 billion in free cash flow through 2030, assuming that oil prices average $50 a barrel. With crude well over that level, ConocoPhillips could produce an even bigger gusher. It intends to use those funds to repay debt, grow its dividend, and repurchase shares, all of which should create additional value for its shareholders.\nA growing dividend gusher\nDevon Energy also took advantage of last year's oil market turmoil to make a needle-moving acquisition, merging with WPX Energy in a $12 billion deal. That combination reduced its costs so that Devon could fund its business at $33 WTI this year. Because of that low cost, Devon also launched the industry's first fixed-plus-variable dividend program to return more of its free cash flow to investors. \nWith oil prices rising, Devon Energy's dividend payments have become bigger. In addition to its base quarterly dividend rate of $0.11 per share, Devon has paid out additional dividends of $0.19, $0.23, and $0.38 per share over the last three quarters. \nThe variable payments will likely continue rising. Devon only realized $50.34 per barrel for its oil during the second quarter because its oil hedges cost it $13.29 per barrel. With those lower-priced hedges about to expire, Devon's cash flow should keep rising even if crude prices cool off. It plans to pay out up to 50% of its free cash flow via variable dividends each quarter, suggesting investors could continue reaping a windfall. \nAccelerating the plan\nPioneer Natural Resources also took advantage of the oil market turmoil to bolster its oil business over the past year. It acquired Parsley Energy in a $7.6 billion deal last October and spent $6.4 billion to purchase DoublePoint Energy this April. Both transactions increased its scale in the Permian Basin, which helped reduce its costs so that it can produce more oil for less money. \nPioneer's initial plan was to start returning some of its growing free cash flow to shareholders next year by adopting a similar dividend framework as Devon. However, booming oil prices drove Pioneer to accelerate its variable dividend program by declaring its first additional payment in August. At $1.51 per share, it was almost triple its base dividend of $0.51 per share. With oil prices rallying and Pioneer's cost-saving initiatives starting to deliver results, that payout could continue growing in the coming quarters. \nCashing in on higher crude oil prices\nConocoPhillips, Devon Energy, and Pioneer Natural Resources took advantage of last year's oil market turbulence to bolster their oil businesses by making needle-moving acquisitions. Those deals boosted their oil production while reducing costs, positioning all three to generate more cash flow. Because of that, they're cashing in on higher oil prices these days. That's giving them the funds to reward investors with higher dividends and share repurchases. Those shareholder returns will likely continue growing along with oil prices, making this trio stand out as some of the top oil stocks to consider buying as crude oil barrels toward $85.","news_type":1},"isVote":1,"tweetType":1,"viewCount":482,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":857389869,"gmtCreate":1635508315326,"gmtModify":1635508315440,"author":{"id":"3585806154552757","authorId":"3585806154552757","name":"stardustttt","avatar":"https://static.tigerbbs.com/acd24cad26743061551c18540659b201","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"Great ariticle, would you like to share it?","listText":"Great ariticle, would you like to share it?","text":"Great ariticle, would you like to share it?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/857389869","repostId":"1140565656","repostType":2,"repost":{"id":"1140565656","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1635508153,"share":"https://www.laohu8.com/m/news/1140565656?lang=&edition=full","pubTime":"2021-10-29 19:49","market":"us","language":"en","title":"AbbVie got a shot in the arm from newer drug sales and lifted profit view","url":"https://stock-news.laohu8.com/highlight/detail?id=1140565656","media":"Tiger Newspress","summary":"U.S. drugmaker AbbVie Inc(ABBV.N)on Friday raised its 2021 adjusted profit forecast for the third ti","content":"<p>U.S. drugmaker AbbVie Inc(ABBV.N)on Friday raised its 2021 adjusted profit forecast for the third time this year after a stellar performance by its newer drugs helped it beat Wall Street estimates for quarterly revenue.</p>\n<p>The company has been focusing on gaining expanded approvals and driving growth for Skyrizi and Rinvoq, launched in 2019, as it prepares for competition for its blockbuster rheumatoid arthritis drug, Humira.</p>\n<p>Humira is the world's highest selling medicine, accounting for nearly 40% of AbbVie's total sales. The company's newer drugs, Skyrizi and Rinvoq, are approved to treat the same conditions as Humira.</p>\n<p>Humira sales, which rose 5.6% to $5.43 billion in the third quarter, are expected to be squeezed when generic rivals enter the U.S. market in 2023.</p>\n<p>Rinvoq sales could take a near-term hit, analysts have said, after the U.S. drug regulator asked the company and others to present information about the risks of death and serious conditions from the use of their drugs that belong to a class of treatments known as JAK inhibitors.</p>\n<p>Meanwhile, Rinvoq sales more than doubled to $453 million in the quarter ended Sept. 30, beating the average analyst estimate of $436.8 million, according to Refinitiv IBES estimates.</p>\n<p>Sales of Skyrizi jumped 83.3% to $796 million, also above estimates of $765 million.</p>\n<p>Revenue from Botox, used as an anti-wrinkle injection and for other cosmetic purposes, also beat estimates.</p>\n<p>Total sales for AbbVie rose 11.2% to $14.34 billion, narrowly beating estimates of $14.32 billion.</p>\n<p>AbbVie now expects full-year adjusted profit of $12.63 to $12.67 per share, compared with prior expectation of $12.52 to $12.62.</p>\n<p>Its shares jumped over 1% in premarket trading.<img src=\"https://static.tigerbbs.com/440c6dd8a91b64d48b36982f3b62340e\" tg-width=\"766\" tg-height=\"565\" width=\"100%\" height=\"auto\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AbbVie got a shot in the arm from newer drug sales and lifted profit view</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbbVie got a shot in the arm from newer drug sales and lifted profit view\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-10-29 19:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>U.S. drugmaker AbbVie Inc(ABBV.N)on Friday raised its 2021 adjusted profit forecast for the third time this year after a stellar performance by its newer drugs helped it beat Wall Street estimates for quarterly revenue.</p>\n<p>The company has been focusing on gaining expanded approvals and driving growth for Skyrizi and Rinvoq, launched in 2019, as it prepares for competition for its blockbuster rheumatoid arthritis drug, Humira.</p>\n<p>Humira is the world's highest selling medicine, accounting for nearly 40% of AbbVie's total sales. The company's newer drugs, Skyrizi and Rinvoq, are approved to treat the same conditions as Humira.</p>\n<p>Humira sales, which rose 5.6% to $5.43 billion in the third quarter, are expected to be squeezed when generic rivals enter the U.S. market in 2023.</p>\n<p>Rinvoq sales could take a near-term hit, analysts have said, after the U.S. drug regulator asked the company and others to present information about the risks of death and serious conditions from the use of their drugs that belong to a class of treatments known as JAK inhibitors.</p>\n<p>Meanwhile, Rinvoq sales more than doubled to $453 million in the quarter ended Sept. 30, beating the average analyst estimate of $436.8 million, according to Refinitiv IBES estimates.</p>\n<p>Sales of Skyrizi jumped 83.3% to $796 million, also above estimates of $765 million.</p>\n<p>Revenue from Botox, used as an anti-wrinkle injection and for other cosmetic purposes, also beat estimates.</p>\n<p>Total sales for AbbVie rose 11.2% to $14.34 billion, narrowly beating estimates of $14.32 billion.</p>\n<p>AbbVie now expects full-year adjusted profit of $12.63 to $12.67 per share, compared with prior expectation of $12.52 to $12.62.</p>\n<p>Its shares jumped over 1% in premarket trading.<img src=\"https://static.tigerbbs.com/440c6dd8a91b64d48b36982f3b62340e\" tg-width=\"766\" tg-height=\"565\" width=\"100%\" height=\"auto\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABBV":"艾伯维公司"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1140565656","content_text":"U.S. drugmaker AbbVie Inc(ABBV.N)on Friday raised its 2021 adjusted profit forecast for the third time this year after a stellar performance by its newer drugs helped it beat Wall Street estimates for quarterly revenue.\nThe company has been focusing on gaining expanded approvals and driving growth for Skyrizi and Rinvoq, launched in 2019, as it prepares for competition for its blockbuster rheumatoid arthritis drug, Humira.\nHumira is the world's highest selling medicine, accounting for nearly 40% of AbbVie's total sales. The company's newer drugs, Skyrizi and Rinvoq, are approved to treat the same conditions as Humira.\nHumira sales, which rose 5.6% to $5.43 billion in the third quarter, are expected to be squeezed when generic rivals enter the U.S. market in 2023.\nRinvoq sales could take a near-term hit, analysts have said, after the U.S. drug regulator asked the company and others to present information about the risks of death and serious conditions from the use of their drugs that belong to a class of treatments known as JAK inhibitors.\nMeanwhile, Rinvoq sales more than doubled to $453 million in the quarter ended Sept. 30, beating the average analyst estimate of $436.8 million, according to Refinitiv IBES estimates.\nSales of Skyrizi jumped 83.3% to $796 million, also above estimates of $765 million.\nRevenue from Botox, used as an anti-wrinkle injection and for other cosmetic purposes, also beat estimates.\nTotal sales for AbbVie rose 11.2% to $14.34 billion, narrowly beating estimates of $14.32 billion.\nAbbVie now expects full-year adjusted profit of $12.63 to $12.67 per share, compared with prior expectation of $12.52 to $12.62.\nIts shares jumped over 1% in premarket trading.","news_type":1},"isVote":1,"tweetType":1,"viewCount":210,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}
